A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Cell Reports

Volumn 21, Issue 5, 2017, Pages 1140-1149

  Savage, Paul ^a,b   Blanchet Cohen, Alexis ^b,c   Revil, Timothée ^b   Badescu, Dunarel ^b   Saleh, Sadiq M I ^a,b   Wang, Yu Chang ^b   Zuo, Dongmei ^a   Liu, Leah ^a   Bertos, Nicholas R ^a   Munoz Ramos, Valentina ^a   Basik, Mark ^b,c,d   Petrecca, Kevin ^b   Asselah, Jamil ^b   Meterissian, Sarkis ^b   Guiot, Marie Christine ^b   Omeroglu, Atilla ^b   Kleinman, Claudia L ^b,c,d   Park, Morag ^a,b   Ragoussis, Jiannis ^b,e  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

BRCA1 mutation; breast cancer; cell hierarchy; EGFR inhibition; patient derived xenograft; single cell RNA sequencing; therapeutic response; tumor heterogeneity; tumor initiating cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; RNA; BRCA1 PROTEIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; STEM CELL EXPANSION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; ISOLATION AND PURIFICATION; MESENCHYMAL STROMA CELL; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SEQUENCE ANALYSIS;

ANIMALS; BRCA1 PROTEIN; FEMALE; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85034845493     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.10.015     Document Type: Article

References (29)

1. Baselga, J., Arteaga, C.L., Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23 (2005), 2445–2459.
2. Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J.M., et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 23 (2005), 5323–5333.
3. Bierie, B., Pierce, S.E., Kroeger, C., Stover, D.G., Pattabiraman, D.R., Thiru, P., Liu Donaher, J., Reinhardt, F., Chaffer, C.L., Keckesova, Z., Weinberg, R.A., Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl. Acad. Sci. USA 114 (2017), E2337–E2346.
4. Burga, L.N., Hu, H., Juvekar, A., Tung, N.M., Troyan, S.L., Hofstatter, E.W., Wulf, G.M., Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res., 13, 2011, R30.
5. Carey, L.A., Rugo, H.S., Marcom, P.K., Mayer, E.L., Esteva, F.J., Ma, C.X., Liu, M.C., Storniolo, A.M., Rimawi, M.F., Forero-Torres, A., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30 (2012), 2615–2623.
6. Chung, W., Eum, H.H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H.S., Kim, S., Lee, J.E., Park, Y.H., et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun., 8, 2017, 15081.
7. Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., Wicha, M.S., In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17 (2003), 1253–1270.
8. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
9. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007), 555–567.
10. Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726.
11. Iyer, G., Hanrahan, A.J., Milowsky, M.I., Al-Ahmadie, H., Scott, S.N., Janakiraman, M., Pirun, M., Sander, C., Socci, N.D., Ostrovnaya, I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 2012, 221.
12. Lawson, D.A., Bhakta, N.R., Kessenbrock, K., Prummel, K.D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526 (2015), 131–135.
13. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., Pietenpol, J.A., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 (2011), 2750–2767.
14. Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., Hilsenbeck, S.G., Pavlick, A., Zhang, X., Chamness, G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008), 672–679.
15. Liedtke, C., Mazouni, C., Hess, K.R., André, F., Tordai, A., Mejia, J.A., Symmans, W.F., Gonzalez-Angulo, A.M., Hennessy, B., Green, M., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26 (2008), 1275–1281.
16. Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., Asselin-Labat, M.-L., Gyorki, D.E., Ward, T., Partanen, A., et al., kConFab. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15 (2009), 907–913.
17. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
18. Maubec, E., Petrow, P., Scheer-Senyarich, I., Duvillard, P., Lacroix, L., Gelly, J., Certain, A., Duval, X., Crickx, B., Buffard, V., et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J. Clin. Oncol. 29 (2011), 3419–3426.
19. Mody, K., Strauss, E., Lincer, R., Frank, R.C., Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer, 10, 2010, 570.
20. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., Arteaga, C.L., Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61 (2001), 8887–8895.
21. Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., Regev, A., Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33 (2015), 495–502.
22. Schneider, M.R., Yarden, Y., The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene 35 (2016), 2949–2960.
23. Shaffer, S.M., Dunagin, M.C., Torborg, S.R., Torre, E.A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P.A., Xiao, M., et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546 (2017), 431–435.
24. Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 (2012), 395–399.
25. Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I., Kris, M.G., Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000), 4885–4892.
26. Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., Rinn, J.L., The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32 (2014), 381–386.
27. Visvader, J.E., Stingl, J., Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev. 28 (2014), 1143–1158.
28. von Minckwitz, G., Jonat, W., Fasching, P., du Bois, A., Kleeberg, U., Lück, H.J., Kettner, E., Hilfrich, J., Eiermann, W., Torode, J., Schneeweiss, A., A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat. 89 (2005), 165–172.
29. Wakeling, A.E., Guy, S.P., Woodburn, J.R., Ashton, S.E., Curry, B.J., Barker, A.J., Gibson, K.H., ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002), 5749–5754.